Synteract acquired leading dermatology CRO Cu-Tech

| By | Clinical Trials
0
210

Synteract, an innovative contract research organization (CRO) providing full-service Phase I-IV clinical trials, has acquired Cu-Tech, LLC, the leading dermatology specialist CRO.

In coming together with Cu-Tech, Synteract has created a dedicated center of dermatology development, making the combined company the leading midsized global CRO for dermatology clinical trials.

Cu-Tech is an industry-renowned dermatology CRO with more than two decades of experience, having managed 130+ dermatology trials. Headquartered in New Jersey, USA, Cu-Tech is known for its strong relationships with its clients and investigative sites, as well as for its expertise in working across a variety of dermatological indications.

By adding a center of development in dermatology, Synteract has positioned itself to better meet sponsors’ specific needs, including addressing stringent trial demands, delivering consistency of study conduct across investigational sites and ensuring accuracy in reporting. Synteract brings international delivery capabilities to the relationship with Cu-Tech as well as specific services in feasibility, biostatistics, clinical operations, data management, medical writing and regulatory expertise.

Synteract has 800 staff members across 21 countries and supports biopharmaceutical companies in all phases of clinical development. The CRO offers a notable depth of expertise in its centers of development in oncology and neuro-degenerative indications, as well as rare and orphan, pediatric, and immunotherapy studies, and now dermatology.

SOURCE: synteract
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.